FDA To Use Rosetta's Syllego to Analyze Genotyping Data in VXDS Program | GenomeWeb
NEW YORK (Genome Web News) - Rosetta Biosoftware said today that the US Food and Drug Administration will use its Syllego software to manage and analyze genotyping data used from genome-wide association studies that are submitted under the FDA’s Voluntary eXploratory Data Submission program.
 
"There are a growing number of genome-wide association study data submissions to the FDA through VXDS," said Weida Tong, director of the Center for Toxicoinformatics at the FDA’s National Center for Toxicological Research.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.